{"title":"Manno-oligosaccharides as a promising antimicrobial strategy: pathogen inhibition and synergistic effects with antibiotics.","authors":"Rachel E Asbury, Bradley A Saville","doi":"10.3389/fmicb.2025.1529081","DOIUrl":null,"url":null,"abstract":"<p><p>Infections caused by pathogenic bacteria pose a significant health challenge to humans and animals, especially given the rising incidence of antimicrobial resistance. Addressing this challenge has resulted in initiatives seeking alternatives to traditional antibiotics. Manno-oligosaccharides (MOS) exhibit pathogen-binding properties, due to their ability to prevent bacterial adhesion to epithelial cells, such as those within the urinary tract and intestinal epithelium. This suggests that MOS could offer a promising alternative to antibiotics. In this study, we explore the ability of various <i>β</i>-MOS products to inhibit the growth of <i>Escherichia coli, Klebsiella pneumoniae, Listeria monocytogenes,</i> and <i>Streptococcus mutans</i>, in addition to their ability to render antibiotics more effective. Inhibition profiles were distinct for each bacterial strain and differed according to <i>β</i>-MOS structure. Antibiotics were significantly potentiated by MOS in some cases, such as ceftazidime against <i>K. pneumoniae</i>. This research shows the role of carbohydrate structure in the anti-bacterial properties of non-digestible oligosaccharides such as MOS and positions MOS as a promising strategy in the treatment of bacterial infections.</p>","PeriodicalId":12466,"journal":{"name":"Frontiers in Microbiology","volume":"16 ","pages":"1529081"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973258/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fmicb.2025.1529081","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Infections caused by pathogenic bacteria pose a significant health challenge to humans and animals, especially given the rising incidence of antimicrobial resistance. Addressing this challenge has resulted in initiatives seeking alternatives to traditional antibiotics. Manno-oligosaccharides (MOS) exhibit pathogen-binding properties, due to their ability to prevent bacterial adhesion to epithelial cells, such as those within the urinary tract and intestinal epithelium. This suggests that MOS could offer a promising alternative to antibiotics. In this study, we explore the ability of various β-MOS products to inhibit the growth of Escherichia coli, Klebsiella pneumoniae, Listeria monocytogenes, and Streptococcus mutans, in addition to their ability to render antibiotics more effective. Inhibition profiles were distinct for each bacterial strain and differed according to β-MOS structure. Antibiotics were significantly potentiated by MOS in some cases, such as ceftazidime against K. pneumoniae. This research shows the role of carbohydrate structure in the anti-bacterial properties of non-digestible oligosaccharides such as MOS and positions MOS as a promising strategy in the treatment of bacterial infections.
期刊介绍:
Frontiers in Microbiology is a leading journal in its field, publishing rigorously peer-reviewed research across the entire spectrum of microbiology. Field Chief Editor Martin G. Klotz at Washington State University is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.